(S (NP-SBJ Transcription/NN factor/NN jun-B/NN) (VP is/VBZ (NP-PRD (NP target/NN) (PP of/IN (NP (NP autoreactive/JJ T-cells/NNS) (PP in/IN (NP IDDM/NN)))))) ./.)
(S (NP-SBJ (NP Target/NN antigens/NNS) (VP defined/VBN (NP */-NONE-) (PP by/IN (NP (NP autoantibodies/NNS) (PP in/IN (NP IDDM/NN)))))) (VP include/VBP (NP-COOD (NP insulin/NN) ,/, (NP (NP a/DT putative/JJ glycolipid/NN) (SBAR (WHNP-41 that/WDT) (S (NP-SBJ *T*-41/-NONE-) (VP reacts/VBZ (PP with/IN (NP islet/NN cell/NN antibodies/NNS)))))) ,/, and/CC (NP (NP a/DT 64,000-M-LRB-r-RRB-/JJ protein/NN) (VP (ADVP-TMP recently/RB) identified/VBN (NP */-NONE-) (PP as/IN (NP glutamic/JJ acid/NN decarboxylase/NN)))))) ./.)
(S (PP In/IN (NP addition/NN)) ,/, (NP-SBJ (NP some/DT IDDM/NN sera/NN) (SBAR (WHNP-42 that/WDT) (S (NP-SBJ *T*-42/-NONE-) (VP contain/VBP (NP (NP antibodies/NNS) (PP to/TO (NP glutamic/JJ acid/NN decarboxylase/NN))))))) (ADVP also/RB) (VP coprecipitate/VBP (NP (NP a/DT 38,000-M-LRB-r-RRB-/JJ protein/NN) (PP from/IN (NP islets/NNS)))) ./.)
(S (NP-SBJ This/DT study/NN) (VP-COOD (VP used/VBD (NP-43 a/DT high/JJ titer/NN anti-38,000-M-LRB-r-RRB-/JJ serum/NN) (S (NP-SBJ *-43/-NONE-) (VP to/TO (VP screen/VB (NP bacteriophage/NN lambda/NN cDNA/NN expression/NN libraries/NNS))))) and/CC (VP identified/VBD (NP (NP-COOD (NP human/JJ islet/NN) and/CC (NP placental/JJ clones/NNS)) (VP encoding/VBG (NP (NP (NP jun-B/NN) ,/, (NP the/DT nuclear/JJ transcription/NN protein/NN) ,/,) (PP of/IN (NP predicted/VBN 38,000/CD M-LRB-r-RRB-/NN))))))) ./.)
(S (NP-SBJ Peripheral/JJ blood/NN T-cells/NNS) (VP exhibited/VBD (NP significant/JJ proliferation/NN) (PP in/IN response/NN to/TO (NP (NP a/DT recombinant/JJ fragment/NN) (PP of/IN (NP (NP (NP jun-B/NN) (PRN -LRB-/-LRB- (NP amino/NN acids/NNS 1-180/CD) -RRB-/-RRB-)) (PP in/IN (NP-COOD (NP (QP (QP 12/CD of/IN 17/CD) (PRN -LRB-/-LRB- (NP 71/CD %/NN) -RRB-/-RRB-)) recent-onset/JJ IDDM/NN subjects/NNS) ,/, (NP (NP (QP (QP 8/CD of/IN 16/CD) (PRN -LRB-/-LRB- (NP 50/CD %/NN) -RRB-/-RRB-)) ICA-positive/JJ first-degree/JJ relatives/NNS) (PP of/IN (NP (NP IDDM/NN subjects/NNS) (SBAR (WHNP-44 who/WP) (S (NP-SBJ *T*-44/-NONE-) (VP were/VBD (PP-PRD at/IN (NP risk/NN)))))))) ,/, (NP (QP (QP 3/CD of/IN 12/CD) (PRN -LRB-/-LRB- (NP 25/CD %/NN) -RRB-/-RRB-)) other/JJ autoimmune/JJ disease/NN subjects/NNS) ,/, and/CC (NP (QP 0/CD of/IN 10/CD) healthy/JJ control/NN subjects/NNS)))))))) ./.)
(S (NP-SBJ (NP Proliferation/NN) (PP to/TO (NP tetanus/NN toxoid/NN))) (VP did/VBD not/RB (VP differ/VB (ADVP significantly/RB) (PP between/IN (NP the/DT groups/NNS)))) ./.)
(S (NP-SBJ (NP Responses/NNS) (PP to/TO (NP jun-B/NN))) (VP were/VBD not/RB (ADJP-PRD related/JJ (PP to/TO (NP-COOD (NP age/NN) ,/, (NP sex/NN) ,/, or/CC (NP human/JJ leukocyte/NN antigen/NN status/NN))))) ./.)
(S (ADVP Thus/RB) ,/, (NP-SBJ-45 autoreactive/JJ T-cells/NNS) (VP-COOD (VP identify/VBP (NP (NP (NP a/DT novel/JJ antigen/NN) ,/, (NP p38/NN jun-B/NN) ,/,) (PP in/IN (NP IDDM/NN)))) and/CC (VP appear/VBP (S (NP-SBJ *-45/-NONE-) (VP to/TO (VP indicate/VB (NP (NP subjects/NNS) (PP at/IN (NP (NP risk/NN) (PP for/IN (NP (NP the/DT development/NN) (PP of/IN (NP clinical/JJ disease/NN)))))))))))) ./.)
